Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04414475 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT04414475 · ClinicalTrials.gov record · last posted 2026-02-02

A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.

StatusRecruiting
PhasePhase 2
Started2020-07-01
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The purpose of this study is to assess the efficacy, antitumor activity, safety and tolerability of selinexor plus low-dose dexamethasone in participants with penta-refractory multiple myeloma or selinexor and bortezomib plus low-dose dexamethasone in participants with triple-class refractory multiple myeloma.

Amendment record 16 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 16 times since 2020-06-02; most recent amendment 2026-01-30. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2020-07-08
Status change Not Yet Recruiting→Recruitingv1
Trial Details
NCT Number NCT04414475
Lead Sponsor Karyopharm Therapeutics Inc
Conditions Multiple Myeloma, Refractory
Enrollment 127 participants
Start Date 2020-07-01
Primary Completion 2028-01 (estimated)
Study Completion 2028-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-02